The GHK-Cu story has a reading room.
These are the sources linked in the story. Each has a particular job; none needs to prove the whole GHK-Cu reputation on its own.
The beginning and the copper distinction
Pickart and colleagues' historical review connects the early observation with skin research. It reports cream findings whose sources aren't all full journal papers. Those findings stay secondhand here.
The collagen work by Maquart's group showed cells making more collagen in a dish. It doesn't establish what a cream or injection would do in a person.
Simeon and colleagues' copper comparison found that GHK-Cu increased a tissue-remodeling enzyme in cells; free GHK didn't. Copper alone did too. That complicates assigning credit.
The skin and hair chapter
Mortazavi and colleagues' delivery review discusses getting the ingredient through skin. It also notes the shortage of clinical testing. Both matter for understanding creams.
Miller and colleagues' post-laser trial found greater satisfaction but no statistically significant objective improvement. Thirteen people completed it, on freshly treated skin. The setting limits the conclusion.
The hair trial by Lee's group tested copper-free GHK alongside another ingredient. The mixture outperformed a dummy lotion on hair count, without a clear difference in thickness. Credit belongs to the combination.
The bigger claims
Campbell and colleagues' lung gene study followed a computer lead with free GHK in cultured human cells. No patients had their emphysema reversed in this experiment.
Pickart and Margolina's gene review explores possible repair-related actions. It isn't one trial proving all those actions help people. That distinction matters when reading the headlines.
Zhang and colleagues' lung study concerns mice with smoke-related damage. Reduced inflammation and oxidative stress remain animal findings. They don't establish human treatment benefits.
Mao and colleagues' colitis study used mice and cells. The material went into the mice's stomachs. It doesn't establish a human injection benefit.
Tucker and colleagues' memory preprint studied nasal delivery in older mice. The linked version hadn't undergone peer review. It isn't a human memory trial.
Endo and colleagues' breakdown study concerns free GHK given into rats' veins. It doesn't supply a human GHK-Cu half-life or injection interval.
The official care pages
FDA's page on safety concerns keeps the injectable GHK-Cu entry in its withdrawn-nomination table, alongside the safety warning. Its content is dated April 22, 2026. That doesn't date this particular withdrawal.
FDA's 503A category list treats non-injectable GHK-Cu separately, under Category 1 evaluation. That conditional enforcement policy isn't drug approval. It doesn't cover the injectable entry.
FDA's compounding answers distinguish prescribing from approval. A compounded medicine lacks FDA approval even when a clinician has prescribed it.
FDA's cosmetic explanation and drug-code directory notes explain two other limits. A cosmetic listing or identification number doesn't establish drug approval.